安德罗格拉福利德通过抑制PI3K/AKT1/RRM2触发的氧化死来缓解2型糖尿病病
Mingzheng Han1, Jingchun Wang1, Shuaihao Guo1
1College of Veterinary Medicine, South China Agricultural University, Guangzhou 510642, China.
Journal of advanced research
|November 7, 2025
概括
安德罗格拉福利德 (AND) 在治疗2型糖尿病病 (T2DN) 方面表现有前途. 它通过向PI3K/AKT1/RRM2-oxeiptosis通路并减少氧化应激,有助于调节血糖和功能.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 2型糖尿病病 (T2DN) 是2型糖尿病的严重并发症,需要改进治疗方法.
- 目前对T2DN的治疗方法需要加强和补充.
研究的目的:
- 研究andrographolide (AND) 作为T2DN.的潜在治疗剂.
- 阐明T2DN和AND治疗效果的潜在分子机制.
主要方法:
- 使用高脂肪/高碳水化合物饮食和链毒素建立了T2DN的犬类模型.
- 管理并评估其对代谢和脏参数的影响.
- 利用转录基因分析和实验验证,确定关键的信号通路 (PI3K/AKT1/RRM2) 和过程 (ROS,氧化死).
主要成果:
- 在T2DN模型中,AND的使用改善了血糖控制,胰岛素敏感性和功能.
- T2DN进展与PI3K/AKT1激活,RRM2上调和ROS驱动的氧化相关.
- 并且有效地抑制PI3K/AKT1/RRM2信号通路,并减轻ROS-oxeiptosis交叉声.
结论:
- AND通过中断一种涉及高血糖,ROS,PI3K/AKT1/RRM2信号传递和氧化的致病级联来证明T2DN的治疗潜力.
- 结果支持AND作为T2DN管理的多目标补充.
- 这项研究为在T2DN治疗中准PI3K/AKT1/RRM2-oxeiptosis轴提供了机制基础.
相关概念视频
01:24Glucagon-like Receptor Agonists
828
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
828
01:22PI3K/mTOR/AKT Signaling Pathway
5.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.3K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
568
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
568
01:27Transducer Mechanism: Enzyme-Linked Receptors
3.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
3.8K
01:23Dipeptidyl Peptidase 4 Inhibitors
570
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
570